Breaking News

Evotec Adds Cell Therapy Mfg. Facility with Rigenerand Acquisition

Expands Evotec’s cell therapy platform EVOcells by adding a dedicated, high-quality cGMP manufacturing site.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Evotec SE signed a definitive agreement to acquire 100% of the capital of Rigenerand Srl, a leading cell technology company, for €23 million. Founded in 2009 as a spin-off of the University of Modena and Reggio Emilia, Rigenerand is a pioneering company in the field of cGMP manufacturing of cell therapies. The acquisition adds a team of cell therapy cGMP manufacturing experts.   Rigenerand is based in Medolla, Italy, near Evotec’s Campus Levi-Montalcini in Verona, and operates a first-class ce...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters